<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37138867</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sj&#xf6;gren's syndrome: evidence- and practice-based guidance.</ArticleTitle><Pagination><StartPage>1117699</StartPage><MedlinePgn>1117699</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1117699</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1117699</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sj&#xf6;gren's syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and refractory/intolerance to conventional immunosuppressants demand other options, namely biological drugs, and small molecules. We aimed to define evidence and practice-based guidance for the off-label use of biologics in SLE, APS, and SS. Recommendations were made by an independent expert panel, following a comprehensive literature review and two consensus rounds. The panel included 17 internal medicine experts with recognized practice in autoimmune disease management. The literature review was systematic from 2014 until 2019 and later updated by cross-reference checking and experts' input until 2021. Preliminary recommendations were drafted by working groups for each disease. A revision meeting with all experts anticipated the consensus meeting held in June 2021. All experts voted (agree, disagree, neither agree nor disagree) during two rounds, and recommendations with at least 75% agreement were approved. A total of 32 final recommendations (20 for SLE treatment, 5 for APS, and 7 for SS) were approved by the experts. These recommendations consider organ involvement, manifestations, severity, and response to previous treatments. In these three autoimmune diseases, most recommendations refer to rituximab, which aligns with the higher number of studies and clinical experience with this biological agent. Belimumab sequential treatment after rituximab may also be used in severe cases of SLE and SS. Second-line therapy with baricitinib, bortezomib, eculizumab, secukinumab, or tocilizumab can be considered in SLE-specific manifestations. These evidence and practice-based recommendations may support treatment decision and, ultimately, improve the outcome of patients living with SLE, APS, or SS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Marinho, Delgado Alves, Fortuna, Faria, Almeida, Alves, Ara&#xfa;jo Correia, Campar, Brand&#xe3;o, Crespo, Marado, Matos-Costa, Oliveira, Salvador, Santos, Silva, Fernandes and Vasconcelos.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marinho</LastName><ForeName>Ant&#xf3;nio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidade de Imunologia Cl&#xed;nica, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMIB - Unidade Multidisciplinar de Investiga&#xe7;&#xe3;o Biom&#xe9;dica, ICBAS - Instituto de Ci&#xea;ncias Biom&#xe9;dicas Abel Salazar, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado Alves</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Unit, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immune Response and Vascular Disease Unit - iNOVA4Health, NOVA Medical School, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuna</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Departamento de Medicina, Centro Hospitalar Universit&#xe1;rio de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faria</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidade de Imunologia Cl&#xed;nica, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMIB - Unidade Multidisciplinar de Investiga&#xe7;&#xe3;o Biom&#xe9;dica, ICBAS - Instituto de Ci&#xea;ncias Biom&#xe9;dicas Abel Salazar, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Unidade de Imunologia Cl&#xed;nica, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMIB - Unidade Multidisciplinar de Investiga&#xe7;&#xe3;o Biom&#xe9;dica, ICBAS - Instituto de Ci&#xea;ncias Biom&#xe9;dicas Abel Salazar, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Gl&#xf3;ria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Hospital da Senhora da Oliveira - Centro Hospitalar Alto Ave, Guimar&#xe3;es, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ara&#xfa;jo Correia</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidade de Imunologia Cl&#xed;nica, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMIB - Unidade Multidisciplinar de Investiga&#xe7;&#xe3;o Biom&#xe9;dica, ICBAS - Instituto de Ci&#xea;ncias Biom&#xe9;dicas Abel Salazar, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campar</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidade de Imunologia Cl&#xed;nica, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMIB - Unidade Multidisciplinar de Investiga&#xe7;&#xe3;o Biom&#xe9;dica, ICBAS - Instituto de Ci&#xea;ncias Biom&#xe9;dicas Abel Salazar, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand&#xe3;o</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidade de Imunologia Cl&#xed;nica, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMIB - Unidade Multidisciplinar de Investiga&#xe7;&#xe3;o Biom&#xe9;dica, ICBAS - Instituto de Ci&#xea;ncias Biom&#xe9;dicas Abel Salazar, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crespo</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Departamento de Medicina, Centro Hospitalar Universit&#xe1;rio de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marado</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Departamento de Medicina, Centro Hospitalar Universit&#xe1;rio de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matos-Costa</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Hospital Distrital de Santar&#xe9;m, Santar&#xe9;m, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Unit, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unidade de Doen&#xe7;as Autoimunes, Servi&#xe7;o de Medicina Interna, Centro Hospitalar de Tr&#xe1;s-os-Montes e Alto Douro, Vila Real, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Lelita</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Departamento de Medicina, Centro Hospitalar Universit&#xe1;rio de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Linha de Investiga&#xe7;&#xe3;o Cl&#xed;nica e Interdisciplinar em Meio Ambiente, Gen&#xe9;tica e Oncobiologia (CIMAGO), Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>F&#xe1;tima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Medicina Interna, Departamento de Medicina, Centro Hospitalar Universit&#xe1;rio de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Milene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Real-World Evidence &amp; Late Phase, CTI Clinical Trial &amp; Consulting Services Unipessoal Lda, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasconcelos</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidade de Imunologia Cl&#xed;nica, Centro Hospitalar Universit&#xe1;rio do Porto, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMIB - Unidade Multidisciplinar de Investiga&#xe7;&#xe3;o Biom&#xe9;dica, ICBAS - Instituto de Ci&#xea;ncias Biom&#xe9;dicas Abel Salazar, Universidade do Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="Y">Biological Products</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sj&#xf6;gren&#x2019;s syndrome</Keyword><Keyword MajorTopicYN="N">antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">biological therapies</Keyword><Keyword MajorTopicYN="N">recommendations</Keyword><Keyword MajorTopicYN="N">small molecules</Keyword><Keyword MajorTopicYN="N">systemic autoimmune diseases</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>AM received consulting, speaker, and advisory board fees from AbbVie, Lilly, MSD, Novartis, Pfizer, and Roche, speaker fees from BMS and Janssen, consulting fees from Janssen and Takeda; and received support for attending meetings from AbbVie, Janssen, Novartis, and Pfizer. JDA received consulting, speaker, and advisory board fees from AbbVie, Lilly, and Novartis, and consulting fees from Pfizer. CV received advisory board fees from AstraZeneca, GSK, Janssen, Novartis, and Pfizer. MF is an employee of a contract research organization (CTI Clinical Trial &amp; Consulting Services) that provides services to several pharmaceutical companies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>2</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37138867</ArticleId><ArticleId IdType="pmc">PMC10150407</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1117699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rose NR. Prediction and prevention of autoimmune disease in the 21st century: A review and preview. Am J Epidemiol (2016) 183(5):403&#x2013;6. doi:&#xa0;10.1093/aje/kwv292</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv292</ArticleId><ArticleId IdType="pubmed">26888748</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. . Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis (2019) 78(6):736&#x2013;45. doi:&#xa0;10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammuller M. The emerging jamboree of transformative therapies for autoimmune diseases. Front Immunol (2020) 11:472. doi:&#xa0;10.3389/fimmu.2020.00472</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00472</ArticleId><ArticleId IdType="pmc">PMC7137386</ArticleId><ArticleId IdType="pubmed">32296421</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell (2020) 181(1):63&#x2013;80. doi:&#xa0;10.1016/j.cell.2020.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.007</ArticleId><ArticleId IdType="pubmed">32243797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. . Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol (2019) 10:1990. doi:&#xa0;10.3389/fimmu.2019.01990</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01990</ArticleId><ArticleId IdType="pmc">PMC6743223</ArticleId><ArticleId IdType="pubmed">31555262</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: An update. BMC Med (2013) 11:88. doi:&#xa0;10.1186/1741-7015-11-88</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-88</ArticleId><ArticleId IdType="pmc">PMC3616818</ArticleId><ArticleId IdType="pubmed">23557513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, et al. . International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev (2017) 16(6):650&#x2013;7. doi:&#xa0;10.1016/j.autrev.2017.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.04.011</ArticleId><ArticleId IdType="pubmed">28434948</ArticleId></ArticleIdList></Reference><Reference><Citation>
OCEBM Levels of Evidence Working Group . The Oxford 2011 Levels of Evidence. Oxford: Oxford Centre for Evidence-Based Medicine;  (2011). Available at: http://www.cebm.net/ocebm-levels-of-evidence/.</Citation></Reference><Reference><Citation>Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. . Systemic lupus erythematosus. Nat Rev Dis Primers (2016) 2:16039. doi:&#xa0;10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias G, Cervera R, Boumpas DT, European League Against Rheumatism . Systemic lupus erythematosus: Pathogenesis and clinical features. In: Bijlsma JWJ, editor. EULAR textbook on rheumatic diseases, vol. 5 . London: BMJ / EULAR; (2012). p. 476&#x2013;505.</Citation></Reference><Reference><Citation>Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. . Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med (2006) 119(8):700&#x2013;6. doi:&#xa0;10.1016/j.amjmed.2005.11.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2005.11.034</ArticleId><ArticleId IdType="pubmed">16887417</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. . Treat-to-Target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis (2014) 73(6):958&#x2013;67. doi:&#xa0;10.1136/annrheumdis-2013-205139</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Samotij D, Reich A. Biologics in the treatment of lupus erythematosus: A critical literature review. BioMed Res Int (2019) 2019:8142368. doi:&#xa0;10.1155/2019/8142368</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/8142368</ArticleId><ArticleId IdType="pmc">PMC6668536</ArticleId><ArticleId IdType="pubmed">31396534</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Ther Adv Musculoskelet Dis (2019) 11:1759720X19874309. doi:&#xa0;10.1177/1759720X19874309</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X19874309</ArticleId><ArticleId IdType="pmc">PMC6755633</ArticleId><ArticleId IdType="pubmed">31565077</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus. Lupus (2016) 25(14):1587&#x2013;96. doi:&#xa0;10.1177/0961203316655215</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316655215</ArticleId><ArticleId IdType="pmc">PMC5089223</ArticleId><ArticleId IdType="pubmed">27488472</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. . Effects of belimumab, a b lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis (2012) 71(11):1833&#x2013;8. doi:&#xa0;10.1136/annrheumdis-2011-200831</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2011-200831</ArticleId><ArticleId IdType="pmc">PMC3465857</ArticleId><ArticleId IdType="pubmed">22550315</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al. . Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis (2014) 73(5):838&#x2013;44. doi:&#xa0;10.1136/annrheumdis-2012-202865</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202865</ArticleId><ArticleId IdType="pmc">PMC3995218</ArticleId><ArticleId IdType="pubmed">23524886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al. . Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus (2016) 25(7):699&#x2013;709. doi:&#xa0;10.1177/0961203315625119</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315625119</ArticleId><ArticleId IdType="pmc">PMC4958991</ArticleId><ArticleId IdType="pubmed">26936891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. . Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol (2014) 41(2):300&#x2013;9. doi:&#xa0;10.3899/jrheum.121368</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.121368</ArticleId><ArticleId IdType="pubmed">24187095</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med (2020) 383(12):1117&#x2013;28. doi:&#xa0;10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Trentin F, Gatto M, Zen M, Larosa M, Maddalena L, Nalotto L, et al. . Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: A review of observational clinical-practice-based. Clin Rev Allergy Immunol (2018) 54(2):331&#x2013;43. doi:&#xa0;10.1007/s12016-018-8675-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-018-8675-2</ArticleId><ArticleId IdType="pmc">PMC6132773</ArticleId><ArticleId IdType="pubmed">29512034</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R. Lupus low disease activity state (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Post-hoc analysis of the phase IIb MUSE trial of anifrolumab. Ann Rheum Dis (2018) 77(5):706&#x2013;13. doi:&#xa0;10.1136/annrheumdis-2017-212504</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212504</ArticleId><ArticleId IdType="pmc">PMC5909750</ArticleId><ArticleId IdType="pubmed">29420200</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. . Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol (2017) 69(2):376&#x2013;86. doi:&#xa0;10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med (2020) 382(3):211&#x2013;21. doi:&#xa0;10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: A decision aid for development of entry criteria for clinical trials. J Rheumatol (1998) 25(2):277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9489819</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum (1999) 42(12):2682&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616018</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 62(1):222&#x2013;33. doi:&#xa0;10.1002/art.27233</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27233</ArticleId><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum (2012) 64(4):1215&#x2013;26. doi:&#xa0;10.1002/art.34359</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, et al. . Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: Results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (2018) 57(3):470&#x2013;9. doi:&#xa0;10.1093/rheumatology/kex395</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex395</ArticleId><ArticleId IdType="pmc">PMC5850287</ArticleId><ArticleId IdType="pubmed">29216396</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, et al. . Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (Graid). Lupus (2013) 22(11):1142&#x2013;9. doi:&#xa0;10.1177/0961203313503912</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313503912</ArticleId><ArticleId IdType="pubmed">24057058</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. . Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum (2010) 62(8):2458&#x2013;66. doi:&#xa0;10.1002/art.27541</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27541</ArticleId><ArticleId IdType="pubmed">20506527</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, et al. . Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian multicentre registry. Clin Exp Rheumatol (2015) 33(4):449&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">26053285</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, et al. . Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus (2018) 27(5):802&#x2013;11. doi:&#xa0;10.1177/0961203317749047</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317749047</ArticleId><ArticleId IdType="pubmed">29308726</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Nebro A, de la Fuente JL, Carreno L, Izquierdo MG, Tomero E, Rua-Figueroa I, et al. . Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The lesimab study. Lupus (2012) 21(10):1063&#x2013;76. doi:&#xa0;10.1177/0961203312446627</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312446627</ArticleId><ArticleId IdType="pubmed">22786985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, et al. . Rituximab as maintenance treatment for systemic lupus erythematosus: A multicenter observational study of 147 patients. Arthritis Rheumatol (2019) 71(10):1670&#x2013;80. doi:&#xa0;10.1002/art.40932</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40932</ArticleId><ArticleId IdType="pubmed">31102498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman RA, Hira-Kazal R, Yee CS, Toescu V, Gordon C. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol (2015) 34(2):263&#x2013;71. doi:&#xa0;10.1007/s10067-014-2839-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-014-2839-0</ArticleId><ArticleId IdType="pubmed">25564308</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, et al. . Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol (2020) 42(1):77&#x2013;93. doi:&#xa0;10.1590/2175-8239-jbn-2018-0254</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/2175-8239-jbn-2018-0254</ArticleId><ArticleId IdType="pmc">PMC7213927</ArticleId><ArticleId IdType="pubmed">31904761</ArticleId></ArticleIdList></Reference><Reference><Citation>Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: An updated systematic review and meta-analysis. Lupus (2013) 22(14):1489&#x2013;503. doi:&#xa0;10.1177/0961203313509295</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313509295</ArticleId><ArticleId IdType="pubmed">24135078</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H, Almoallim H. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol (2018) 5(2):118&#x2013;26. doi:&#xa0;10.5152/eurjrheum.2018.17096</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2018.17096</ArticleId><ArticleId IdType="pmc">PMC6072690</ArticleId><ArticleId IdType="pubmed">30185361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Li H, Zhong H, Zhou T. Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther (2019) 13:845&#x2013;56. doi:&#xa0;10.2147/DDDT.S195113</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S195113</ArticleId><ArticleId IdType="pmc">PMC6417005</ArticleId><ArticleId IdType="pubmed">30880917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotagiri P, Martin A, Hughes P, Becker G, Nicholls K. Single-dose rituximab in refractory lupus nephritis. Intern Med J (2016) 46(8):899&#x2013;901. doi:&#xa0;10.1111/imj.13136</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.13136</ArticleId><ArticleId IdType="pubmed">27242250</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. . Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study. Rheumatology (2014) 53(9):1570&#x2013;7. doi:&#xa0;10.1093/rheumatology/ket462</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket462</ArticleId><ArticleId IdType="pubmed">24505125</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, et al. . Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore) (2017) 96(27):e7429. doi:&#xa0;10.1097/MD.0000000000007429</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000007429</ArticleId><ArticleId IdType="pmc">PMC5502178</ArticleId><ArticleId IdType="pubmed">28682905</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, et al. . Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev (2012) 11(5):357&#x2013;64. doi:&#xa0;10.1016/j.autrev.2011.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.10.009</ArticleId><ArticleId IdType="pubmed">22032879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Tao MJ, Jin LR, Sheng J, Li Z, Peng H, et al. . Effectiveness and safety of common therapeutic drugs for refractory lupus nephritis: A network meta-analysis. Exp Ther Med (2020) 19(1):665&#x2013;71. doi:&#xa0;10.3892/etm.2019.8257</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2019.8257</ArticleId><ArticleId IdType="pmc">PMC6923745</ArticleId><ArticleId IdType="pubmed">31897105</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang B, Li T, Guo L, Shen H, Ye S, Chen S. Efficacy and safety of rituximab in systemic lupus erythematosus and Sj&#xf6;gren syndrome patients with refractory thrombocytopenia: A retrospective study of 21 cases. J Clin Rheumatol (2015) 21(5):244&#x2013;50. doi:&#xa0;10.1097/RHU.0000000000000273</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000273</ArticleId><ArticleId IdType="pmc">PMC4539196</ArticleId><ArticleId IdType="pubmed">26203828</ArticleId></ArticleIdList></Reference><Reference><Citation>Serris A, Amoura Z, Canoui-Poitrine F, Terrier B, Hachulla E, Costedoat-Chalumeau N, et al. . Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol (2018) 93(3):424&#x2013;9. doi:&#xa0;10.1002/ajh.24999</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.24999</ArticleId><ArticleId IdType="pubmed">29247540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: Long-term follow-up and review of the literature. Lupus (2013) 22(7):664&#x2013;74. doi:&#xa0;10.1177/0961203313485489</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313485489</ArticleId><ArticleId IdType="pubmed">23612795</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavo-Blanco M, Novella-Navarro M, Caliz-Caliz R, Ferrer-Gonzalez MA. Rituximab in refractory autoimmune hemolytic anemia in systemic lupus erythematosus. Reumatol Clin (Engl Ed) (2018) 14(4):248&#x2013;9. doi:&#xa0;10.1016/j.reuma.2017.07.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2017.07.023</ArticleId><ArticleId IdType="pubmed">28870533</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao SH, Chang YL, Yen JC, Liao HT, Wu TH, Yu CL, et al. . Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: A systematic review and meta-analysis. Exp Hematol Oncol (2020) 9:6. doi:&#xa0;10.1186/s40164-020-00163-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-020-00163-5</ArticleId><ArticleId IdType="pmc">PMC7161265</ArticleId><ArticleId IdType="pubmed">32322437</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Ishikawa Y, Ishikawa J, Fujiwara M, Kita Y. Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab. Immunol Med (2019) 42(4):185&#x2013;8. doi:&#xa0;10.1080/25785826.2019.1696644</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/25785826.2019.1696644</ArticleId><ArticleId IdType="pubmed">31794352</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: Current approaches and future perspectives. Drugs (2016) 76(4):459&#x2013;83. doi:&#xa0;10.1007/s40265-015-0534-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-015-0534-3</ArticleId><ArticleId IdType="pmc">PMC4791452</ArticleId><ArticleId IdType="pubmed">26809245</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. . Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2007) 66(4):470&#x2013;5. doi:&#xa0;10.1136/ard.2006.057885</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.057885</ArticleId><ArticleId IdType="pmc">PMC1856059</ArticleId><ArticleId IdType="pubmed">17107983</ArticleId></ArticleIdList></Reference><Reference><Citation>Narvaez J, Rios-Rodriguez V, de la Fuente D, Estrada P, Lopez-Vives L, Gomez-Vaquero C, et al. . Rituximab therapy in refractory neuropsychiatric lupus: Current clinical evidence. Semin Arthritis Rheum (2011) 41(3):364&#x2013;72. doi:&#xa0;10.1016/j.semarthrit.2011.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.06.004</ArticleId><ArticleId IdType="pubmed">21875742</ArticleId></ArticleIdList></Reference><Reference><Citation>Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus: A systematic review. Int J Rheum Dis (2014) 17(5):494&#x2013;501. doi:&#xa0;10.1111/1756-185X.12337</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12337</ArticleId><ArticleId IdType="pubmed">24673755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Qian J, Gu Y, Chen X, Ye S. Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol (2011) 30(7):981&#x2013;6. doi:&#xa0;10.1007/s10067-011-1714-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-011-1714-5</ArticleId><ArticleId IdType="pubmed">21340494</ArticleId></ArticleIdList></Reference><Reference><Citation>Chessa E, Piga M, Floris A, Mathieu A, Cauli A. Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: An alternative to standard of care. Open Access Rheumatol (2017) 9:167&#x2013;70. doi:&#xa0;10.2147/OARRR.S143768</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S143768</ArticleId><ArticleId IdType="pmc">PMC5602683</ArticleId><ArticleId IdType="pubmed">28979169</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeletti A, Baraldi O, Chiocchini AL, Comai G, Cravedi P, La Manna G. Rituximab as first-line therapy in severe lupus erythematosus with neuropsychiatric and renal involvement: A case-report and review of the literature. J Clin Case Rep (2017) 7(10):1033. doi:&#xa0;10.4172/2165-7920.10001033</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2165-7920.10001033</ArticleId><ArticleId IdType="pmc">PMC5991483</ArticleId><ArticleId IdType="pubmed">29888753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualtierotti R, Borghi MO, Gerosa M, Schioppo T, Larghi P, Geginat J, et al. . Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: A case series. Clin Exp Rheumatol (2018) 36(4):643&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29533753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, et al. . Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant (2021) 36(8):1474&#x2013;83. doi:&#xa0;10.1093/ndt/gfaa117</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfaa117</ArticleId><ArticleId IdType="pmc">PMC8311580</ArticleId><ArticleId IdType="pubmed">32591783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, et al. . The net-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun (2018) 91:45&#x2013;54. doi:&#xa0;10.1016/j.jaut.2018.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.03.003</ArticleId><ArticleId IdType="pubmed">29636274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Huizinga TW, Rabelink TJ, Teng YK. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (2014) 53(11):2122&#x2013;4. doi:&#xa0;10.1093/rheumatology/keu369</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu369</ArticleId><ArticleId IdType="pubmed">25205827</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonetta F, Allali D, Roux-Lombard P, Chizzolini C. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine (2017) 84(2):235&#x2013;6. doi:&#xa0;10.1016/j.jbspin.2016.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2016.01.008</ArticleId><ArticleId IdType="pubmed">27238199</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. . phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol (2021) 73(1):121&#x2013;31. doi:&#xa0;10.1002/art.41466</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41466</ArticleId><ArticleId IdType="pmc">PMC7839443</ArticleId><ArticleId IdType="pubmed">32755035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichikawa T, Shimojima Y, Kishida D, Kaneko T, Sekijima Y. Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: Case-based review. Rheumatol Int (2021) 41(5):1009&#x2013;17. doi:&#xa0;10.1007/s00296-020-04569-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04569-6</ArticleId><ArticleId IdType="pubmed">32253501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, et al. . Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT-LUPUS) protocol: A prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open (2019) 9(12):e032569. doi:&#xa0;10.1136/bmjopen-2019-032569</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-032569</ArticleId><ArticleId IdType="pmc">PMC6937022</ArticleId><ArticleId IdType="pubmed">31848169</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, et al. . phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open (2019) 9(3):e025687. doi:&#xa0;10.1136/bmjopen-2018-025687</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-025687</ArticleId><ArticleId IdType="pmc">PMC6475247</ArticleId><ArticleId IdType="pubmed">30898822</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranow C, Allaart C, Amoura Z. Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: The phase 3, randomized, placebo-controlled BLISS-BELIEVE study. Arthritis Rheumatol (2021) 73(Suppl 9):L13.</Citation></Reference><Reference><Citation>Alunno A, Padjen I, Fanouriakis A, Boumpas DT. Pathogenic and therapeutic relevance of Jak/Stat signaling in systemic lupus erythematosus: Integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells (2019) 8(8):898. doi:&#xa0;10.3390/cells8080898</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8080898</ArticleId><ArticleId IdType="pmc">PMC6721755</ArticleId><ArticleId IdType="pubmed">31443172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. . Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet (2018) 392(10143):222&#x2013;31. doi:&#xa0;10.1016/S0140-6736(18)31363-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId><ArticleId IdType="pubmed">30043749</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan K, Huang G, Sang X, Xu A. Baricitinib for systemic lupus erythematosus. Lancet (2019) 393(10170):402. doi:&#xa0;10.1016/S0140-6736(18)32763-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32763-6</ArticleId><ArticleId IdType="pubmed">30712894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW. Baricitinib for systemic lupus erythematosus - authors' reply. Lancet (2019) 393(10170):402&#x2013;3. doi:&#xa0;10.1016/S0140-6736(18)32749-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32749-1</ArticleId><ArticleId IdType="pubmed">30712893</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Sarfert R, Klotsche J, Kuhl AA, Rubbert-Roth A, Lorenz HM, et al. . The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis (2015) 74(7):1474&#x2013;8. doi:&#xa0;10.1136/annrheumdis-2014-206016</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206016</ArticleId><ArticleId IdType="pmc">PMC4484251</ArticleId><ArticleId IdType="pubmed">25710470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, et al. . The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus (2017) 26(9):952&#x2013;8. doi:&#xa0;10.1177/0961203316686703</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316686703</ArticleId><ArticleId IdType="pubmed">28059023</ArticleId></ArticleIdList></Reference><Reference><Citation>Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. . Efficacy and safety of bortezomib in refractory lupus nephritis: A single-center experience. Lupus (2020) 29(2):118&#x2013;25. doi:&#xa0;10.1177/0961203319896018</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319896018</ArticleId><ArticleId IdType="pubmed">31865857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhou W, Zhang Z. Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient. Rheumatology (2015) 54(1):194&#x2013;5. doi:&#xa0;10.1093/rheumatology/keu393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu393</ArticleId><ArticleId IdType="pubmed">25288787</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartuccio L, Rupolo M, Michieli M, De Vita S. Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology (2014) 53(2):381&#x2013;2. doi:&#xa0;10.1093/rheumatology/ket284</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket284</ArticleId><ArticleId IdType="pubmed">23962626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, et al. . Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol (2018) 28(6):986&#x2013;92. doi:&#xa0;10.1080/14397595.2018.1432331</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1432331</ArticleId><ArticleId IdType="pubmed">29363990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjowall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: Description of two cases. Lupus (2017) 26(12):1333&#x2013;8. doi:&#xa0;10.1177/0961203317691371</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317691371</ArticleId><ArticleId IdType="pubmed">28162031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. . Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence. Rheumatol Int (2017) 37(8):1249&#x2013;55. doi:&#xa0;10.1007/s00296-017-3686-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3686-5</ArticleId><ArticleId IdType="pubmed">28258475</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Matis L, Rollins S, Mojcik C. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus. Arthritis Rheum (2004) 50:S35&#x2013;S747.</Citation></Reference><Reference><Citation>Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, et al. . Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (2015) 54(12):2286&#x2013;8. doi:&#xa0;10.1093/rheumatology/kev307</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev307</ArticleId><ArticleId IdType="pmc">PMC4643725</ArticleId><ArticleId IdType="pubmed">26316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono M, Ohashi N, Namikawa A, Katahashi N, Ishigaki S, Tsuji N, et al. . A rare case of lupus nephritis presenting as thrombotic microangiopathy with diffuse pseudotubulization possibly caused by atypical hemolytic uremic syndrome. Intern Med (2018) 57(11):1617&#x2013;23. doi:&#xa0;10.2169/internalmedicine.0228-17</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.0228-17</ArticleId><ArticleId IdType="pmc">PMC6028688</ArticleId><ArticleId IdType="pubmed">29434134</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol (2020) 21(1):245. doi:&#xa0;10.1186/s12882-020-01888-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-020-01888-5</ArticleId><ArticleId IdType="pmc">PMC7329551</ArticleId><ArticleId IdType="pubmed">32605540</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine (2015) 72(2):146&#x2013;53. doi:&#xa0;10.1016/j.cyto.2014.12.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2014.12.027</ArticleId><ArticleId IdType="pubmed">25647269</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, et al. . A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus (2018) 27(7):1202&#x2013;6. doi:&#xa0;10.1177/0961203318762598</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318762598</ArticleId><ArticleId IdType="pubmed">29523055</ArticleId></ArticleIdList></Reference><Reference><Citation>Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. . Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 62(2):542&#x2013;52. doi:&#xa0;10.1002/art.27221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27221</ArticleId><ArticleId IdType="pmc">PMC3057537</ArticleId><ArticleId IdType="pubmed">20112381</ArticleId></ArticleIdList></Reference><Reference><Citation>Juptner M, Zeuner R, Schreiber S, Laudes M, Schroder JO. Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment. Lupus (2014) 23(4):428&#x2013;30. doi:&#xa0;10.1177/0961203314520844</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314520844</ArticleId><ArticleId IdType="pubmed">24482144</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeshima K, Ishii K, Torigoe M, Imada C, Iwakura M, Hamasaki H, et al. . Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. Lupus (2012) 21(9):1003&#x2013;6. doi:&#xa0;10.1177/0961203312441046</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312441046</ArticleId><ArticleId IdType="pubmed">22433919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocampo V, Haaland D, Legault K, Mittoo S, Aitken E. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous. BMJ Case Rep (2016) 2016:bcr2016215423. doi:&#xa0;10.1136/bcr-2016-215423</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2016-215423</ArticleId><ArticleId IdType="pmc">PMC4986022</ArticleId><ArticleId IdType="pubmed">27503940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep (2012) 2012:bcr2012007834. doi:&#xa0;10.1136/bcr-2012-007834</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2012-007834</ArticleId><ArticleId IdType="pmc">PMC4544961</ArticleId><ArticleId IdType="pubmed">23264273</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Ocana-Medina C, Sanchez-Roman J. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (2012) 51(10):1918&#x2013;9. doi:&#xa0;10.1093/rheumatology/kes072</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes072</ArticleId><ArticleId IdType="pubmed">22513150</ArticleId></ArticleIdList></Reference><Reference><Citation>Group AT. Treatment of lupus nephritis with abatacept: The abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol (2014) 66(11):3096&#x2013;104. doi:&#xa0;10.1002/art.38790</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38790</ArticleId><ArticleId IdType="pmc">PMC4528976</ArticleId><ArticleId IdType="pubmed">25403681</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. . Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol (2014) 66(2):379&#x2013;89. doi:&#xa0;10.1002/art.38260</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38260</ArticleId><ArticleId IdType="pubmed">24504810</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. . The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 62(10):3077&#x2013;87. doi:&#xa0;10.1002/art.27601</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27601</ArticleId><ArticleId IdType="pubmed">20533545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain C, Colman PJ, Ranger AM, Burkly LC, Johnston GI, Otoul C, et al. . Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis (2017) 76(11):1837&#x2013;44. doi:&#xa0;10.1136/annrheumdis-2017-211388</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211388</ArticleId><ArticleId IdType="pubmed">28780512</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Bruce IN, D&#xf6;rner T, Leon MG, Leszczy&#x144;ski P, Urowitz M, et al. . Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (2021) 60(11):5397&#x2013;407. doi:&#xa0;10.1093/rheumatology/keab381</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab381</ArticleId><ArticleId IdType="pmc">PMC9194804</ArticleId><ArticleId IdType="pubmed">33956056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. . Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med (2020) 383(12):1149&#x2013;55. doi:&#xa0;10.1056/NEJMoa2023325</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId><ArticleId IdType="pubmed">32937047</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcin Mutlu M, Wacker J, Tascilar K, Taubmann J, Manger B, Kr&#xf6;nke G, et al. . Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus&#x2013;associated refractory cerebral vasculitis induces immune tolerance. Rheumatology (2023) 62(2):e21&#x2013;e3. doi:&#xa0;10.1093/rheumatology/keac393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac393</ArticleId><ArticleId IdType="pubmed">35801920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatol (Oxford England) (2015) 54(3):383&#x2013;91. doi:&#xa0;10.1093/rheumatology/keu429</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu429</ArticleId><ArticleId IdType="pmc">PMC4334686</ArticleId><ArticleId IdType="pubmed">25406359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakthiswary R, D'Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: A systematic review and meta-analysis. Medicine (2014) 93(16):e86. doi:&#xa0;10.1097/md.0000000000000086</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000000086</ArticleId><ArticleId IdType="pmc">PMC4616295</ArticleId><ArticleId IdType="pubmed">25310743</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte AC, Sousa S, Nunes T, Cordeiro A, Gon&#xe7;alves P. Intravenous human immunoglobulin for the treatment of severe longitudinal extensive transverse myelitis associated with systemic lupus erythematous. Acta Reumatol Port (2018) 43(2):154&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30091960</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Riemekasten G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol (2019) 31(2):208&#x2013;12. doi:&#xa0;10.1097/BOR.0000000000000575</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000575</ArticleId><ArticleId IdType="pubmed">30562181</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 10(1):202. doi:&#xa0;10.1186/ar2341</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2341</ArticleId><ArticleId IdType="pmc">PMC2374473</ArticleId><ArticleId IdType="pubmed">18226185</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, et al. . Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: Long-term follow-up of 13 patients. Rheumatology (2009) 48(11):1451&#x2013;4. doi:&#xa0;10.1093/rheumatology/kep270</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep270</ArticleId><ArticleId IdType="pubmed">19748965</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. . B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2021) 81(1):100&#x2013;7. doi:&#xa0;10.1136/annrheumdis-2021-220920</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, et al. . Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis (2017) 76(11):1829&#x2013;36. doi:&#xa0;10.1136/annrheumdis-2017-211191</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211191</ArticleId><ArticleId IdType="pmc">PMC5705851</ArticleId><ArticleId IdType="pubmed">28684557</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (2018) 57(7):1156&#x2013;61. doi:&#xa0;10.1093/rheumatology/key042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key042</ArticleId><ArticleId IdType="pubmed">29562252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A, M&#xfc;ller F, Mougiakakos D, B&#xf6;ltz S, Wilhelm A, Aigner M, et al. . Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med (2022) 28(10):2124&#x2013;32. doi:&#xa0;10.1038/s41591-022-02017-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId><ArticleId IdType="pubmed">36109639</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. . Antiphospholipid syndrome. Nat Rev Dis Primers (2018) 4:17103. doi:&#xa0;10.1038/nrdp.2017.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.103</ArticleId><ArticleId IdType="pubmed">29321641</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ram&#xf3;n E, et al. . Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis (2015) 74(6):1011&#x2013;8. doi:&#xa0;10.1136/annrheumdis-2013-204838</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204838</ArticleId><ArticleId IdType="pubmed">24464962</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano R, Pons-Estel GJ, Espinosa G, Quintana RM, Reverter JC, Tassies D, et al. . Long-term follow-up of antiphospholipid syndrome: Real-life experience from a single center. Lupus (2020) 29(9):1050&#x2013;9. doi:&#xa0;10.1177/0961203320933009</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320933009</ArticleId><ArticleId IdType="pubmed">32536318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol (2016) 28(3):218&#x2013;27. doi:&#xa0;10.1097/BOR.0000000000000269</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000269</ArticleId><ArticleId IdType="pmc">PMC4958413</ArticleId><ArticleId IdType="pubmed">26927441</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. . EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis (2019) 78(10):1296&#x2013;304. doi:&#xa0;10.1136/annrheumdis-2019-215213</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Rodr&#xed;guez-Pint&#xf3; I, Colafrancesco S, Conti F, Valesini G, Ros&#xe1;rio C, et al. . 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev (2014) 13(7):699&#x2013;707. doi:&#xa0;10.1016/j.autrev.2014.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.03.002</ArticleId><ArticleId IdType="pubmed">24657970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. . Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus (2011) 20(2):206&#x2013;18. doi:&#xa0;10.1177/0961203310395803</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310395803</ArticleId><ArticleId IdType="pubmed">21303837</ArticleId></ArticleIdList></Reference><Reference><Citation>Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, et al. . Mcmaster RARE-bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemostasis (2018) 16(8):1656&#x2013;64. doi:&#xa0;10.1111/jth.14192</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14192</ArticleId><ArticleId IdType="pubmed">29978552</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Autoimmun Rev (2016) 15(3):226&#x2013;35. doi:&#xa0;10.1016/j.autrev.2015.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.11.009</ArticleId><ArticleId IdType="pubmed">26656906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew GS, Cho J, Lateef A. Microangiopathic antiphospholipid antibody-associated syndrome in a pregnant lady. Lupus (2017) 26(4):435&#x2013;7. doi:&#xa0;10.1177/0961203316659548</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316659548</ArticleId><ArticleId IdType="pubmed">27694537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffatti A, Favaro M, Hoxha A, Zambon A, Marson P, Del Ross T, et al. . Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A Prospective Study. J Reprod Immunol (2016) 115:14&#x2013;9. doi:&#xa0;10.1016/j.jri.2016.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jri.2016.03.004</ArticleId><ArticleId IdType="pubmed">27088752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar N, Kosowicz R, Hook K. Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. J Thromb Thrombolysis (2014) 38(2):196&#x2013;200. doi:&#xa0;10.1007/s11239-014-1061-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-014-1061-x</ArticleId><ArticleId IdType="pubmed">24549974</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N, Yamaguchi K, Motomura K, Hisano M, Sago H, Murashima A. Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome. Clin Exp Rheumatol (2014) 32(2):299&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">24447427</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S, Shen J, Ni J, Gong Y, Zhu H. Cutaneous gangrene of the arms and legs after cardiopulmonary resuscitation: A rare presentation of catastrophic antiphospholipid syndrome. Am J Emergency Med (2017) 35(1):191 e3&#x2013; e5. doi:&#xa0;10.1016/j.ajem.2016.06.086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2016.06.086</ArticleId><ArticleId IdType="pubmed">27396539</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum AN, Anavekar NS, Ernste FC, Mankad SV, Le RJ, Manocha KK, et al. . A case of catastrophic antiphospholipid syndrome: First report with advanced cardiac imaging using MRI. Lupus (2015) 24(12):1338&#x2013;41. doi:&#xa0;10.1177/0961203315587960</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315587960</ArticleId><ArticleId IdType="pubmed">26014099</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi VJ, Leventhal JS, Mensah KA, Galan A, Choate KA. Cyanosis of the foot. Cutis (2017) 100(4):206.</Citation><ArticleIdList><ArticleId IdType="pubmed">29136053</ArticleId></ArticleIdList></Reference><Reference><Citation>Martis N, Blanchouin E, Lazdunski R, Lechtman S, Robert A, Hyvernat H, et al. . A therapeutic challenge: Catastrophic anti-phospholipid syndrome with diffuse alveolar haemorrhage. Immunologic Res (2015) 62(2):222&#x2013;4. doi:&#xa0;10.1007/s12026-015-8649-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-015-8649-x</ArticleId><ArticleId IdType="pubmed">25906846</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman H, Rodriguez-Pinto I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, et al. . Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev (2013) 12(11):1085&#x2013;90. doi:&#xa0;10.1016/j.autrev.2013.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.05.004</ArticleId><ArticleId IdType="pubmed">23777822</ArticleId></ArticleIdList></Reference><Reference><Citation>Horikoshi M, Inokuma S, Matsubara E, Honda Y, Okada R, Kobuna M, et al. . Atypical subacute recurrence of catastrophic antiphospholipid syndrome in a Japanese female patient. Intern Med (2015) 54(22):2923&#x2013;7. doi:&#xa0;10.2169/internalmedicine.54.5150</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.54.5150</ArticleId><ArticleId IdType="pubmed">26568011</ArticleId></ArticleIdList></Reference><Reference><Citation>Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Semin Arthritis Rheum (2015) 44(6):652&#x2013;7. doi:&#xa0;10.1016/j.semarthrit.2014.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2014.10.013</ArticleId><ArticleId IdType="pubmed">25481816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CR, Liu MF. Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: A single-center experience. Semin Arthritis Rheum (2016) 46(1):102&#x2013;8. doi:&#xa0;10.1016/j.semarthrit.2016.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2016.02.002</ArticleId><ArticleId IdType="pubmed">26992634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Bazzan M, Roccatello D. Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med (2017) 12(1):1&#x2013;7. doi:&#xa0;10.1007/s11739-016-1596-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-016-1596-2</ArticleId><ArticleId IdType="pubmed">28044251</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioszegi A, Tarr T, Nagy-Vincze M, Nanasy-Vass M, Veisz R, Bidiga L, et al. . Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: The beneficial effect of rituximab treatment. Lupus (2018) 27(9):1552&#x2013;8. doi:&#xa0;10.1177/0961203318768890</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318768890</ArticleId><ArticleId IdType="pubmed">29635999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gkogkolou P, Ehrchen J, Goerge T. Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab. J Dermatol Treat (2017) 28(6):564&#x2013;6. doi:&#xa0;10.1080/09546634.2017.1282599</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09546634.2017.1282599</ArticleId><ArticleId IdType="pubmed">28084106</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum (2013) 65(2):464&#x2013;71. doi:&#xa0;10.1002/art.37759</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37759</ArticleId><ArticleId IdType="pubmed">23124321</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormile I, Granata F, Punziano A, de Paulis A, Rossi FW. Immunosuppressive treatment in antiphospholipid syndrome: Is it worth it? Biomedicines (2021) 9(2):132. doi:&#xa0;10.3390/biomedicines9020132</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9020132</ArticleId><ArticleId IdType="pmc">PMC7911562</ArticleId><ArticleId IdType="pubmed">33535377</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, et al. . Eculizumab in refractory catastrophic antiphospholipid syndrome: A case report and systematic review of the literature. Clin Exp Med (2019) 19(3):281&#x2013;8. doi:&#xa0;10.1007/s10238-019-00565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-019-00565-8</ArticleId><ArticleId IdType="pubmed">31214910</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. . Sjogren syndrome. Nat Rev Dis Primers (2016) 2(1):16047. doi:&#xa0;10.1038/nrdp.2016.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.47</ArticleId><ArticleId IdType="pubmed">27383445</ArticleId></ArticleIdList></Reference><Reference><Citation>Both T, Dalm VASH, van Hagen PM, van Daele PLA. Reviewing primary Sj&#xf6;gren's syndrome: Beyond the dryness - from pathophysiology to diagnosis and treatment. Int J Med Sci (2017) 14(3):191&#x2013;200. doi:&#xa0;10.7150/ijms.17718</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.17718</ArticleId><ArticleId IdType="pmc">PMC5370281</ArticleId><ArticleId IdType="pubmed">28367079</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, et al. . Treatment guidelines for rheumatologic manifestations of Sj&#xf6;gren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) (2017) 69(4):517&#x2013;27. doi:&#xa0;10.1002/acr.22968</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22968</ArticleId><ArticleId IdType="pubmed">27390247</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano S, Isenberg DA. Present and novel biologic drugs in primary Sjogren's syndrome. Clin Exp Rheumatol (2019) 37 Suppl 118(3):167&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">31025931</ArticleId></ArticleIdList></Reference><Reference><Citation>Price EJ, Rauz S, Tappuni AR, Sutcliffe N, Hackett KL, Barone F, et al. . The British Society for Rheumatology guideline for the management of adults with primary Sj&#xf6;gren's syndrome. Rheumatology (2017) 56(10):e24&#x2013;48. doi:&#xa0;10.1093/rheumatology/kex166</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex166</ArticleId><ArticleId IdType="pubmed">28957550</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Zeron P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, et al. . Efficacy and safety of topical and systemic medications: A systematic literature review informing the EULAR recommendations for the management of Sjogren's syndrome. RMD Open (2019) 5(2):e001064. doi:&#xa0;10.1136/rmdopen-2019-001064</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2019-001064</ArticleId><ArticleId IdType="pmc">PMC6827762</ArticleId><ArticleId IdType="pubmed">31749986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zeron P, Bombardieri S, Bootsma H, De Vita S, Dorner T, et al. . EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis (2020) 79(1):3&#x2013;18. doi:&#xa0;10.1136/annrheumdis-2019-216114</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216114</ArticleId><ArticleId IdType="pubmed">31672775</ArticleId></ArticleIdList></Reference><Reference><Citation>Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puechal X, et al. . Treatment of primary Sj&#xf6;gren's syndrome with rituximab: A randomized trial. Ann Intern Med (2014) 160(4):233&#x2013;42. doi:&#xa0;10.7326/M13-1085</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M13-1085</ArticleId><ArticleId IdType="pubmed">24727841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. . Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj&#xf6;gren's syndrome. Arthritis Rheumatol (2017) 69(7):1440&#x2013;50. doi:&#xa0;10.1002/art.40093</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40093</ArticleId><ArticleId IdType="pubmed">28296257</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza FB, Porfirio GJ, Andriolo BN, Albuquerque JV, Trevisani VF. Rituximab effectiveness and safety for treating primary Sj&#xf6;gren's syndrome (pSS): Systematic review and meta-analysis. PloS One (2016) 11(3):e0150749. doi:&#xa0;10.1371/journal.pone.0150749</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150749</ArticleId><ArticleId IdType="pmc">PMC4801187</ArticleId><ArticleId IdType="pubmed">26998607</ArticleId></ArticleIdList></Reference><Reference><Citation>Letaief H, Lukas C, Barnetche T, Gaujoux-Viala C, Combe B, Morel J. Efficacy and safety of biological DMARDs modulating B cells in primary Sj&#xf6;gren's syndrome: Systematic review and meta-analysis. Joint Bone Spine (2018) 85(1):15&#x2013;22. doi:&#xa0;10.1016/j.jbspin.2017.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2017.06.004</ArticleId><ArticleId IdType="pubmed">28673789</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Chavez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Masso C, et al. . Severe, life-threatening phenotype of primary Sj&#xf6;gren's syndrome: Clinical characterisation and outcomes in 1580 patients (GEAS-SS registry). Clin Exp Rheumatol (2018) 36 Suppl 112(3):121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30156546</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluin PM, Roodenburg JL, et al. . Treatment of mucosa-associated lymphoid tissue lymphoma in Sj&#xf6;gren's syndrome: A retrospective clinical study. J Rheumatol (2011) 38(10):2198&#x2013;208. doi:&#xa0;10.3899/jrheum.110077</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.110077</ArticleId><ArticleId IdType="pubmed">21844152</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. . Effectiveness of rituximab treatment in primary Sj&#xf6;gren's syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 62(4):960&#x2013;8. doi:&#xa0;10.1002/art.27314</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27314</ArticleId><ArticleId IdType="pubmed">20131246</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. . A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum (2012) 64(3):843&#x2013;53. doi:&#xa0;10.1002/art.34331</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34331</ArticleId><ArticleId IdType="pubmed">22147661</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, et al. . Efficacy of rituximab in systemic manifestations of primary Sj&#xf6;gren's syndrome: Results in 78 patients of the autoimmune and rituximab registry. Ann Rheum Dis (2013) 72(6):1026&#x2013;31. doi:&#xa0;10.1136/annrheumdis-2012-202293</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202293</ArticleId><ArticleId IdType="pubmed">23264337</ArticleId></ArticleIdList></Reference><Reference><Citation>Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. . Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj&#xf6;gren's syndrome. Ann Rheum Dis (2007) 66(3):351&#x2013;7. doi:&#xa0;10.1136/ard.2006.057919</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.057919</ArticleId><ArticleId IdType="pmc">PMC1856024</ArticleId><ArticleId IdType="pubmed">16950808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, Callejas JL, Martinez-Berriotxoa A, Pallares L, et al. . Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol (2010) 28(4):468&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">20525449</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiras M, Sousa F, Brand&#xe3;o M, Oliveira D, Faria R, Campar A, et al. . P117 rituximab therapy for primary Sj&#xf6;gren's syndrome &#x2013; a retrospective single-centre study. Lupus Sci Med (2020) 7(Suppl 1):A85&#x2013;A. doi:&#xa0;10.1136/lupus-2020-eurolupus.161</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-eurolupus.161</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. . Efficacy and safety of belimumab given for 12 months in primary Sj&#xf6;gren's syndrome: The BELISS open-label phase II study. Rheumatology (2015) 54(12):2249&#x2013;56. doi:&#xa0;10.1093/rheumatology/kev257</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev257</ArticleId><ArticleId IdType="pubmed">26242856</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. . Efficacy and safety of belimumab in primary Sj&#xf6;gren's syndrome: Results of the BELISS open-label phase II study. Ann Rheum Dis (2015) 74(3):526&#x2013;31. doi:&#xa0;10.1136/annrheumdis-2013-203991</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203991</ArticleId><ArticleId IdType="pubmed">24347569</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado AC, Dos Santos LC, Fidelix T, Lekwitch I, Soares SB, Gasparini AF, et al. . Effectiveness and safety of abatacept for the treatment of patients with primary Sj&#xf6;gren's syndrome. Clin Rheumatol (2020) 39(1):243&#x2013;8. doi:&#xa0;10.1007/s10067-019-04724-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-019-04724-w</ArticleId><ArticleId IdType="pubmed">31420813</ArticleId></ArticleIdList></Reference><Reference><Citation>Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. . Efficacy and safety of abatacept in active primary Sj&#xf6;gren's syndrome: Results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis (2020) 80(3):339&#x2013;48. doi:&#xa0;10.1136/annrheumdis-2020-218599</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218599</ArticleId><ArticleId IdType="pmc">PMC7892395</ArticleId><ArticleId IdType="pubmed">33168545</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nimwegen JF, Mossel E, van Zuiden GS, Wijnsma RF, Delli K, Stel AJ, et al. . Abatacept treatment for patients with early active primary Sj&#xf6;gren's syndrome: A single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol (2020) 2(3):e153&#x2013;e63. doi:&#xa0;10.1016/S2665-9913(19)30160-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30160-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheumatic Dis (2021) 80(1):14&#x2013;25. doi:&#xa0;10.1136/annrheumdis-2020-218272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazitt T, Eviatar T, Shear J, Meidan R, Furer V, Feld J, et al. . Development of autoantibodies following BNT162b2 mRNA COVID-19 vaccination and their association with disease flares in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and the general population: Results of 1-year prospective follow-up study. Vaccines (Basel) (2023) 11(2):476. doi:&#xa0;10.3390/vaccines11020476</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020476</ArticleId><ArticleId IdType="pmc">PMC9958930</ArticleId><ArticleId IdType="pubmed">36851352</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Orsi A, Span&#xf2; F, Puppo F, Durando P, Icardi G, et al. . Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. Autoimmun Rev (2014) 13(2):75&#x2013;84. doi:&#xa0;10.1016/j.autrev.2013.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.07.007</ArticleId><ArticleId IdType="pubmed">24044940</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M, Mufti N, Palmore TN, Hasni SA. Recommendations and barriers to vaccination in systemic lupus erythematosus. Autoimmun Rev (2018) 17(10):990&#x2013;1001. doi:&#xa0;10.1016/j.autrev.2018.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.04.006</ArticleId><ArticleId IdType="pmc">PMC6150817</ArticleId><ArticleId IdType="pubmed">30103044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>